Relay Therapeutics, Inc. Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

RLAY

Rang în acțiuni #4017
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Preț acțiune
$18.65
Ultima sincronizare: 2026-10-20
Capitalizare de piață
$4.09B
Schimbare (1 zi)
9.15%
Schimbare (1 an)
164.96%
Țară
US
Tranzacționează Relay Therapeutics, Inc. (RLAY)

Categorie

Healthcare
Venituri pentru Relay Therapeutics, Inc. (RLAY)
Venituri în Jun 2026 TTM: $10.35M
Conform celor mai recente rapoarte financiare ale Relay Therapeutics, Inc., venitul actual al companiei (TTM) este $10.35M. În anul 2023, compania a avut un venit de $25.55M o creștere față de venitul din anul 2022, care a fost de $1.38M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Relay Therapeutics, Inc. din 2018 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $10.35M 3.43%
2024 $10.01M -60.83%
2023 $25.55M 1,749.82%
2022 $1.38M -54.41%
2021 $3.03M -96.34%
2020 $82.65M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$12.62B 121,873.91%
US
$2.23B 21,426.57%
US
$15.74B 152,019.10%
AU
- -
CH
$6.02B 58,076.69%
NL